[Ustekinumab - Current position]
- PMID: 30103222
- DOI: 10.1055/a-0655-2425
[Ustekinumab - Current position]
Abstract
The present review by the IBD-Dach group provides a comprehensive summary of the mode of action, clinical development, approval, efficacy and safety aspects of the novel anti-p40 antibody Ustekinumab. The review provides current data, including the large clinical trials as well as smaller case series and work outside the field of inflammatory bowel diseases for shedding more light into special situations. Together, the data indicate that Ustekinumab shows clinical efficacy as well as a good safety profile for the treatment of Crohn's disease.
Die vorliegende Übersicht der IBD-Dach-Gruppe legt eine Übersicht zu Wirkmechanismus, klinischer Entwicklung, Zulassung, Wirksamkeit und Sicherheitsaspekten des neuen Anti-p40-Antikörpers Ustekinumab vor, der für die Therapie des moderaten bis schweren Morbus Crohn zugelassen ist. Die Arbeit fasst die aktuelle Datenlage zusammen und enthält somit sowohl die Daten der Zulassungsstudien als auch die Daten aus kleineren und auch fachübergreifenden Arbeiten, mit denen die Aspekte zu besonderen Situationen diskutiert werden können. Alle Arbeiten zusammen zeigen, dass mit Ustekinumab eine wirksame und sichere Option für den Morbus Crohn zur Verfügung steht.
© Georg Thieme Verlag KG Stuttgart · New York.
Conflict of interest statement
Britta Siegmund: received a research grant from Pfizer, served as consultant for Falk, Janssen, MSD, Abbvie, Celgene, Lilly, Takeda, Pfizer, Hospira and received lecture fees from Abbvie, Falk, Ferring, Janssen, MSD, Merck, Takeda; all money went to the Charité – Universitätsmedizin Berlin, Germany. Christoph Högenauer: Beratungs- und Vortragstätigkeit für Janssen-Cilag Pharma GmbHGottfried Novacek: Advisory Board/Speaker: Janssen, MSD, Abbvie, Falk, Pfizer, ViforWolfgang Petritsch: Abbvie, Astro-Pharma, Falk, Ferring, Janssen, MSD, Takeda und ViforWalter Reinisch: has received research funding from Abbott Laboratories, Abbvie, Aesca, Centocor, Falk Pharma GmbH, Immundiagnsotik, and MSD; WR has served as a speaker for Abbott Laboratories, Abbvie, Aesca, Aptalis, Centocor, Celltrion, Danone Austria, Elan, Falk Pharma GmbH, Ferring, Immundiagnostik, Mitsubishi Tanabe Pharma Corporation, MSD, Otsuka, PDL, Pharmacosmos, Schering-Plough, Shire, Takeda, Therakos, Vifor, and Yakult; WR has served as a consultant for Abbott Laboratories, Abbvie, Aesca, Amgen, AM Pharma, Astellas, Astra Zeneca, Avaxia, Bioclinica, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Covance, Danone Austria, Elan, Falk Pharma GmbH, Ferring, Galapagos, Genentech, Gilead, Grünenthal, ICON, Index Pharma, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nestle, Novartis, Ocera, Otsuka, PDL, Pharmacosmos, Pfizer, Procter & Gamble, Prometheus, Robarts Clinical Trial, Schering-Plough, Second Genome, Setpointmedical, Takeda, Therakos, Tigenix, UCB, Vifor, Zyngenia, and 4SC; and WR has served as an advisory board member for Abbott Laboratories, Abbvie, Aesca, Amgen, AM Pharma, Astellas, Astra Zeneca, Avaxia, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Danone Austria, Elan, Ferring, Galapagos, Genentech, Grünenthal, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, MedImmune, Millenium, Mitsubishi Tanabe Pharma Corporation, MSD, Nestle, Novartis, Ocera, Otsuka, PDL, Pharmacosmos, Pfizer, Procter & Gamble, Prometheus, Schering-Plough, Second Genome, Setpointmedical, Takeda, Therakos, Tigenix, UCB, Zyngenia, and 4SCAlain Schoepfer: Advisory Board: Vifor, Abbvie, MSD, UCB in der SchweizStefan Schreiber received consultancy fees from AbbVie, Bristol-Myers Squibb, Boehringer, Ferring, Genentech/Roche, Pfizer, MSD/Janssen, Takeda and UCB and lecture fees from AbbVie, MSD/Janssen, Takeda and UCBStephan Vavricka: Consulting fees, payment for lectures, support for travel to meetings, advisory boards, unrestricted research grants: Abbott, Ferring, MSD, Pfizer, Takeda, Tillots, UCB, ViforBernd Bokemeyer: Consulting Fee: Abbvie, MSD, Shire, Ferring, UCB, Hospira,Takeda, Shield Therapeutics, Pfizer, Biogen, Janssen, Hexal, Cellgene; Allergan, Boehringer, Falk Speaking and Teaching: Abbvie, Ferring, MSD, Merckle, Falk, HLR, Grant/Research: Abbvie, Ferring, UCB, Janssen, Takeda
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
